Compare Dolby Laboratories, Inc. (DLB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs TransMedics Group Inc — how do they compare? Dolby Laboratories, Inc. trades at $61.28 (market cap $5.75B), while TransMedics Group Inc trades at $87 (market cap $3.10B). The key difference: Dolby Laboratories, Inc. is the larger of the two by market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DLB | TMDX | |
|---|---|---|
Market Cap | $5.75B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $75.62 | $150.42 |
52-Week Low | $48.51 | $61.99 |
Enterprise Value | $5.12B | $3.49B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $60.74, down 2.19% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with an 87.61% gross margin and has beaten EPS estimates for four consecutive quarters. Recent news highlights innovation in automotive and broadcast licensing, though revenue growth remains choppy.
The stock presents a compelling opportunity with a consensus price target of $87.50, implying significant upside, but faces near-term execution risks and licensing volatility. Long-term growth drivers in premium audio/visual formats are balanced by macroeconomic sensitivity and competitive pressures.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
